Driven Flow™ Point-of-Care Rapid Test Development
Driven Flow™ Technology represents a breakthrough in point-of- care (POC), rapid diagnostic testing. By greatly enhancing the speed, accuracy, and specificity of the canonical lateral flow assay, the patented Driven Flow™ Technology offers a route to true confirmatory and quantitative POC testing for pathogens, drugs and their metabolites, hormones, and other antigens in a wide array of testing environments. Driven Flow™ Technology was developed to exceed the minimum requirements for accuracy and consistency in rapid, in vitro diagnostic (IVD) testing and to make rapid, cost-effective, simple, and quantitative immunological testing a reality. With reliable results in as little as one minute, Driven Flow™ Technology delivers on the “Accuracy at the Speed of ALFA” promise.
ALFA offers our customers access to its patented Driven Flow™ Technology. Just provide your testing specifications, and our experienced team of scientists will adapt our Driven Flow™ Technology to your product. With a long, successful track record for granted US FDA clearances and CE Marks, ALFA is an ideal partner for taking products from design through the required regulatory processes.
Lateral Flow Point-of-Care Rapid Test Development
For three decades lateral flow technology has provided patients, clinicians, and employers with rapid, point-of-care testing for a variety of compounds contained in numerous matrices. From the earliest commercial kits used to test for ovulation and pregnancy, to recent FDA approvals allowing for home collection of samples for the early detection of colorectal cancer, lateral flow technology has remained the standard bearer in immunological testing. Predicated on the ability of antibodies to specifically bind analytes as small as traditional drugs and their metabolites, the range of possible targets for development of a lateral flow assay is nearly limitless.
ALFA customers, including many of the top 10 global diagnostic companies, benefit from our 20-years of experience in developing world class, rapid lateral flow tests. Utilizing our IVD rapid test development competencies, our in-house science team is ready to tackle new challenges presented by our client’s needs. Whether for drugs-of-abuse, fertility, or disease screening, no device is beyond ALFA's expertise to design, regardless of testing matrix (e.g. urine, saliva, blood, solubilized solid).
Speed and accuracy in testing development are not mutually exclusive at ALFA, with project completion times often 50% faster than our competitors, again delivering on our “Accuracy at the Speed of ALFA” promise.